Literature DB >> 825687

The lethality of aranucleotides.

S S Cohen.   

Abstract

Certain D-arabinosyl nucleosides, notably D-arabinosyl cytosine (araC) and D-arabinosyl adenine (araA), are useful in the treatment of certain leukemias and some DNA virus infections, respectively. The compounds are lethal to animal cells and some bacteria. Despite extensive deamination, the parent nucleosides are transported within sensitive cells and phosphorylated to the mono-, di- and triphosphates. AraCTP and araATP are good specific competitive inhibitors of tumor cell or virus-induced DNA polymerases, competing with dCTP and dATP, respectively. In addition to markedly inhibiting DNA synthesis, the aranucleotides enter newly formed DNA in internucleotide linkage. Sensitivity to the nucleosides appears to correlate with the relative ratio of formation of the triphosphate via a nucleoside kinase to degradation of the nucleoside via a nucleoside deaminase. Inhibition of the deaminase increases formation of the aranucleoside triphosphate in leukemic or virus-infected cells and markedly increases the toxicity of the nucleosides. Combinations of inhibitors of the deaminases and of the arnaucleoside are being explored in clinical situations. In addition, the slow penetration of aranucleotides into cells has been observed and some of these 5'-phosphates are useful antiviral agents, e.g. against herpes virus in herpetic keratitis.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 825687

Source DB:  PubMed          Journal:  Med Biol        ISSN: 0302-2137


  9 in total

1.  DNA synthesis as a therapeutic target: the first 65 years.

Authors:  Christopher K Mathews
Journal:  FASEB J       Date:  2012-06       Impact factor: 5.191

2.  CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine.

Authors:  Raphaelle Fanciullino; Laure Farnault; Mélanie Donnette; Diane-Charlotte Imbs; Catherine Roche; Geoffroy Venton; Yael Berda-Haddad; Vadim Ivanov; Joseph Ciccolini; L'Houcine Ouafik; Bruno Lacarelle; Regis Costello
Journal:  Blood Adv       Date:  2018-03-13

3.  Cytosine arabinoside induces ectoderm and inhibits mesoderm expression in human embryonic stem cells during multilineage differentiation.

Authors:  S Jagtap; K Meganathan; J Gaspar; V Wagh; J Winkler; J Hescheler; A Sachinidis
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

4.  Synergistic interaction between 1-beta-D-arabinofuranosylcytosine, thymidine, and hydroxyurea against human B cells and leukemic blasts in vitro.

Authors:  J A Streifel; S B Howell
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

5.  Application of arabinofuranosyl cytosine in the kinetic analysis and quantitation of DNA repair in human cells after ultraviolet irradiation.

Authors:  R D Snyder; W L Carrier; J D Regan
Journal:  Biophys J       Date:  1981-08       Impact factor: 4.033

Review 6.  Vidarabine: a preliminary review of its pharmacological properties and therapeutic use.

Authors:  R Whitley; C Alford; F Hess; R Buchanan
Journal:  Drugs       Date:  1980-10       Impact factor: 9.546

7.  Tetrahydrouridine specifically facilitates deoxycytidine incorporation into herpes simplex virus DNA.

Authors:  T W North; C K Mathews
Journal:  J Virol       Date:  1981-03       Impact factor: 5.103

Review 8.  Evolution of the arabinosides and the pharmacology of fludarabine.

Authors:  W Plunkett; V Gandhi
Journal:  Drugs       Date:  1994       Impact factor: 9.546

9.  Effect of cytosine arabinoside metabolizing enzyme expression on drug toxicity in acute myeloid leukemia.

Authors:  Ajay Abraham; Anup J Devasia; Savitha Varatharajan; Sreeja Karathedath; Poonkuzhali Balasubramanian; Vikram Mathews
Journal:  Ann Hematol       Date:  2014-11-13       Impact factor: 3.673

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.